Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001373604-25-000086
Filing Date
2025-05-30
Accepted
2025-05-30 17:46:45
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 7380
  Complete submission text file 0001373604-25-000086.txt   9038
Mailing Address 65 E CEDAR - SUITE 2 ZIONSVILLE IN 46077
Business Address 65 E CEDAR - SUITE 2 ZIONSVILLE IN 46077 317-344-2447
BML Investment Partners, L.P. (Filed by) CIK: 0001373604 (see all company filings)

EIN.: 383708345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A

Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Subject) CIK: 0001880438 (see all company filings)

EIN.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-93617 | Film No.: 251012500
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)